Nuwellis, Inc. Announces 18 Percent Increase in Revenue for First Quarter 2021 Over Previous Year and Provides Company Update

EDEN PRAIRIE, Minn., May 11, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (previously CHF Solutions, Inc.) announced today its results for the first quarter ended March 31, 2021, which included the following highlights:

  • Completed corporate rebranding from CHF Solutions, Inc. to Nuwellis, Inc. on April 27, 2021
  • Revenue for the first quarter ended March 31, 2021, was $1.9 million, an increase of 18 percent compared to the prior year period
  • Increased Aquadex therapy utilization amongst strategic Critical Care accounts; highest levels seen in the past five quarters
  • Enrolled first pediatric patient into clinical registry in April 2021
  • Received strong endorsements for Category III CPT code application from two major medical societies
  • Ended the quarter with $27.9 million in cash and no debt

“Following our most recent $20.9 million capital raise with net proceeds of $18.9 million on March 19, 2021, Nuwellis is in a strong position to execute against our long-term strategic growth plan,” said Nestor Jaramillo, CEO of Nuwellis. “While COVID-19 headwinds persisted during the quarter, we continue to see strong growth in capital equipment sales and utilization among Critical Care and Pediatric accounts. Lastly, we completed our corporate rebranding to Nuwellis, Inc. in late April 2021. When we expanded the therapeutic focus areas we serve to include pediatrics, critical care and heart failure, we realized our name was no longer a true representation of what we do. As a provider of innovative medical technology, we have an obligation and duty to help improve outcomes for as many patients as possible.”

First Quarter 2021 Financial Results
Revenue for the first quarter of 2021 was $1.9 million, an increase of 18% compared to $1.6 million in the prior year period. Revenue growth in the first quarter of 2021 was primarily driven by increased capital equipment sales and strong utilization within Critical Care. The Company also continued to see increasing utilization among established pediatric accounts during the quarter.

Gross margin was 50.4% for the first quarter 2021, compared to 51.2% in the prior year period. The decline in gross margins was primarily due to strong sales of capital equipment. When compared to the prior year period, first quarter 2021 revenue mix was more heavily weighted towards capital equipment sales in the Critical Care and Pediatric segments. Quarterly gross margins are dependent on revenue mix, but to the extent that the install base of Aquadex systems grows, the Company expects that gross margins will increase with higher levels of consumable utilization.

Selling, general and administrative (“SG&A”) expenses for the first quarter of 2021 were $5.2 million, an increase of 15% compared to the prior year period. The increase in SG&A was primarily due to the timing of non-recurring administrative expenses and continued investment in sales and marketing activities. Research and development (“R&D”) expenses in the first quarter of 2021 were $0.9 million, an increase of 10% compared to the prior year period. The increase in R&D expenses was driven primarily by clinical expenditures related to the pediatric registry.

The net loss for the first quarter of 2021 was $5.2 million, compared to a net loss of $4.6 million in the prior year period.

Cash and cash equivalents were $27.9 million with no debt as of March 31, 2021. During the first quarter of 2021, the Company used $5.4 million of cash in operations. The Company also completed a $20.9 million capital raise with net proceeds of $18.9 million on March 19, 2021.

Webcast and Conference Call Information
The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company’s performance. To access the live webcast, please visit Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 2282685. An audio archive of the webcast will be available following the call at

About Nuwellis
Nuwellis, Inc. (Nasdaq:NUWE), formally CHF Solutions, is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, Minn., with a wholly-owned subsidiary in Ireland. The Company has been listed on the Nasdaq Capital Market since February 2012, previously branded as CHF Solutions (Nasdaq:CHFS).

About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2021 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited, in thousands, except per share amounts)

  Three months ended
March 31,
  2021   2020 
Net sales$1,918  $1,630 
Cost of goods sold 952   796 
Gross margin 966   834 
Operating expenses:       
Selling, general and administrative 5,237   4,537 
Research and development 947   864 
Total operating expenses 6,184   5,401 
Loss from operations (5,218)  (4,567)
Other income (expense), net (1)  1 
Loss before income taxes (5,219)  (4,566)
Income tax expense (2)  (2)
Net loss$(5,221) $(4,568)
Basic and diluted loss per share$(1.25) $(11.54)
Weighted average shares outstanding – basic and diluted 4,212   548 
Other comprehensive loss:       
Foreign currency translation adjustments$(3) $(3)
Total comprehensive loss$(5,224) $(4,571)

Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)

  March 31,
   December 31,
ASSETS (unaudited)     
Current assets       
Cash and cash equivalents$27,893  $14,437 
Accounts receivable 919   905 
Inventory 2,957   2,957 
Other current assets 369   237 
Total current assets 32,138   18,536 
Property, plant and equipment, net 1,219   1,200 
Operating lease right-of-use asset 206   255 
Other assets    21 
TOTAL ASSETS$33,563  $20,012 
Current liabilities     
Accounts payable$1,613  $1,097 
Accrued compensation 1,245   2,192 
Current portion of operating lease liability 212   206 
Current portion of finance lease liability 24   24 
Other current liabilities 69   66 
Total current liabilities 3,163   3,585 
Operating lease liability    55 
Finance lease liability 48   54 
Total liabilities 3,211   3,694 
Commitments and contingencies     
Stockholders’ equity     
Series A junior participating preferred stock as of March 31, 2021 and December 31, 2020, par value $0.0001 per share; authorized 30,000 shares, none outstanding     
Series F convertible preferred stock as of March 31, 2021 and December 31, 2020, par value $0.0001 per share; authorized 127 shares, issued and outstanding 127 shares     
Preferred stock as of March 31, 2021 and December 31, 2020, par value
$0.0001 per share; authorized 39,969,873 shares, none outstanding
Common stock as of March 31, 2021 and December 31, 2020, par value
$0.0001 per share; authorized 100,000,000 shares, issued and outstanding
6,531,942 and 2,736,060, respectively
Additional paid-in capital 268,921   249,663 
Accumulated other comprehensive loss:     
Foreign currency translation adjustment (10)  (7)
Accumulated deficit (238,559)  (233,338)
Total stockholders’ equity 30,352   16,318 

Condensed Consolidated Statements of Cash Flows
(unaudited, in thousands)

  Three months ended
March 31,
Operating Activities:       
Net loss$(5,221) $(4,568)
Adjustments to reconcile net loss to cash flows used in operating activities:       
Depreciation and amortization 126   65 
Stock-based compensation expense, net 355   380 
Loss on disposal of property and equipment    46 
Changes in operating assets and liabilities:       
Accounts receivable (14)  72 
Inventory (89)  (398)
Other current assets (132)  20 
Other assets and liabilities 24   67 
Accounts payable and accrued expenses (431)  (1,179)
Net cash used in operating activities (5,382)  (5,495)
Investing Activities:       
Purchases of property and equipment (56)  (17)
Net cash used in investing activities (56)  (17)
Financing Activities:       
Proceeds from public stock offerings, net 18,902   9,616 
Proceeds from warrant exercises 1   289 
Payments on finance lease liability (6)   
Net cash provided by financing activities 18,897   9,905 
Effect of exchange rate changes on cash (3)  (3)
Net increase in cash and cash equivalents 13,456   4,390 
Cash and cash equivalents - beginning of period 14,437   1,279 
Cash and cash equivalents - end of period$27,893  $5,669 
Supplemental cash flow information       
Inventory transferred to property, plant and equipment$89  $ 


Matt Bacso
Gilmartin Group

Jessica Stebing

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.